IgE Antibody Composition for Cancer Treatment, King's College
Summary
USPTO granted Patent US12606617B2 to King's College London on April 21, 2026. The patent covers a pharmaceutical unit dosage composition comprising an IgE antibody in a dosage of less than 50 mg, intended for administration to mammalian subjects for treating cancer, specifically human ovarian cancers. The patent names four inventors and contains 21 claims.
What changed
USPTO issued Patent US12606617B2 to King's College London for a pharmaceutical unit dosage composition comprising an IgE antibody, wherein the composition comprises less than 50 mg of the IgE antibody. The patent covers methods of treating cancer, particularly human ovarian cancers, using the disclosed composition.
Affected parties include pharmaceutical companies, cancer researchers, and potential licensees interested in IgE antibody-based cancer therapies. The patent creates intellectual property rights that may require freedom-to-operate analysis for competing IgE antibody cancer treatments.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Composition comprising an IgE antibody
Grant US12606617B2 Kind: B2 Apr 21, 2026
Assignee
Kings's College London
Inventors
James Spicer, Sophia Karagiannis, Mariangela Figini, Hannah Gould
Abstract
In one aspect, the present invention relates to a pharmaceutical unit dosage composition comprising an antibody of isotype immunoglobulin E (IgE), wherein the composition comprises less than 50 mg of the IgE antibody. The pharmaceutical unit dosage compositions may be administered to a mammalian subject and find use in treating cancer, in particular, human ovarian cancers.
CPC Classifications
C07K 16/28 C07K 2317/94 C07K 2317/73 A61P 35/00 A61K 2039/505 A61K 2039/545
Filing Date
2021-04-23
Application No.
17919589
Claims
21
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Grants - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.